Summary

Organoids Market Research Report Information By Product and Service (Product and Service), By Type of Organoids (Liver, Kidney, Pancreas, Intestine, Heart, and others), By Application (Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, and Others), By End-Users (Academic and Research Institutes, Pharmaceutical and Biotechnology Company, Contract Research Organizations (CROs), and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Market Overview
The Organoids Market was valued at USD 1.39 billion in 2023. The market is expected to expand from USD 1.68 billion in 2024 to USD 9.16 billion by 2032, with a compound annual growth rate (CAGR) of 23.55% over the forecast period (2024-2032). Rising demand for personalized medication, as well as increased use of drug discovery and toxicology research, are driving market expansion.
The growing desire for personalized treatment is a significant driver of the Organoids Market's growth. Personalized medicine, often known as precision medicine, focuses on personalizing medical therapy to each patient's unique traits. This method takes into account aspects such as genetics, environment, and lifestyle in order to give more effective and focused treatments. Organoids, which are small 3D tissue constructs that imitate the functions and complexity of organs, have emerged as an important tool for enhancing personalized medicine.

Recognizing the significant heterogeneity in how people respond to treatments is an important part of customized medicine. Traditional techniques to drug discovery frequently rely on animal models or 2D cell cultures, which do not truly reflect human biology. Organoids provide a more physiologically appropriate platform for researching disease processes and evaluating medication responses. Researchers can use patient-derived organoids to better understand the specific characteristics of diseases and anticipate how individuals will respond to various therapies.

Market Segment insights
The Organoids Market is split into product and service.
The Organoids Market is divided into six categories: liver, kidney, pancreas, intestine, heart, and others.
The market is divided into five applications: drug testing, developmental biology, personalized medicine, regenerative medicine, and others.
End-users in the Market include academic and research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others.

Regional insights
The Organoids Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America had the biggest market share in 2023 and is expected to reach USD 3.42 billion by 2032, representing a CAGR of 22.88% over the forecast period.

The increased use of organoid-based research models in the biotechnology sector in the United States and Canada is due to technological breakthroughs that have permitted the fabrication of 3D organoids and spheroids. In the United States, large university research institutions and biotechnology corporations have been at the forefront of developing organoid technology.
The Americas area is followed by Europe, which holds the second highest organoids market share. One crucial contributor is Europe's strong research infrastructure and significant investment in life sciences. Countries such as Germany, the United Kingdom, and the Netherlands have world-class research institutions and biotechnology businesses that are at the forefront of organoid research.
The organoids market in Asia Pacific is expanding rapidly, owing to a number of causes. Organoids, three-dimensional tiny organs made from stem cells or tissue, have enormous potential in disease modeling, drug development, and regenerative medicine applications.

Major Players
Major competitors in the Organoids Market include Thermo Fisher Scientific Inc., Inc., Merck KGaA, Corning Incorporated, STEMCELL Technologies, Bio-Techne, Molecular Devices, LLC, and others.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Type
3.8 DATA MODELING
3.8.1 microeconomic factor analysis:
3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Rising demand for personalized medicine
4.2.2 Growing applications in drug discovery and toxicology studies
4.3 RESTRAINTS
4.3.1 Regulatory challenges impacting market growth
4.3.2 High cost of development and maintenance
4.4 OPPORTUNITY
4.4.1 Technological advancements enhancing organoid production and applications
4.5 TREND
4.5.1 Rising investment in regenerative medicine
4.5.2 Expanding use in studying developmental biology
4.6 CHALLENGES
4.6.1 Ethical concerns surrounding organoid sourcing and experimentation
4.6.2 Integration challenges with existing medical practices and technologies
4.7 IMPACT ANALYSIS OF COVID-19
4.7.1 Impact on R & D
4.7.2 Impact on Supply Chain
4.7.3 Impact on Pricing
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 Raw Material Sourcing and Research & Development (R&D)
5.1.2 Organoid Production and Quality Control/Assurance
5.1.3 Distribution and Logistics
5.1.4 Application in Research, Drug Discovery, and Clinical Translation
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 Threat of New Entrants
5.2.2 Bargaining Power of Suppliers
5.2.3 Threat of Substitutes
5.2.4 Bargaining Power of Buyers
5.2.5 Intensity of Rivalry
6 GLOBAL ORGANOIDS MARKET, BY PRODUCT & SERVICE
6.1 OVERVIEW
7 GLOBAL ORGANOIDS MARKET, BY TYPE OF ORGANOIDS
7.1 OVERVIEW
8 GLOBAL ORGANOIDS MARKET, BY APPLICATION
8.1 OVERVIEW
9 GLOBAL ORGANOIDS MARKET, BY END-USERS
9.1 OVERVIEW
10 GLOBAL ORGANOIDS MARKET, BY REGION
10.1 GLOBAL
10.2 NORTH AMERICA
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 EUROPE
10.3.1 germany
10.3.2 France
10.3.3 UK
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 ASIA PACIFIC
10.4.1 china
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 REST OF THE WORLD
10.5.1 Middle East & Africa
10.5.2 South America
11 COMPETITIVE LANDSCAPE
11.1 COMPETITIVE OVERVIEW
11.2 MAJOR PLAYERS IN THE GLOBAL ORGANOIDS MARKET
11.3 COMPETITIVE BENCHMARKING
11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.4.1 Product launch/development
11.4.2 Contract & Agreement
12 COMPANY PROFILES
12.1 HUB ORGANOIDS
12.1.1 Company Overview
12.1.2 FINANCIAL OVERVIEW
12.1.3 Products/Services Offered
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 NEYROBLASTGX
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 STEMCELL TECHNOLOGIES
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 BIO-TECHNE
12.4.1 COMPANY OVERVIEW
12.4.2 Financial Overview
12.4.3 PRODUCTS OFFERED
12.4.4 Key Developments
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 THERMO FISHER SCIENTIFIC INC
12.5.1 COMPANY OVERVIEW
12.5.2 Financial Overview
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 3DNAMICS INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 MOLECULAR DEVICES, LLC
12.7.1 Company Overview
12.7.2 FINANCIAL OVERVIEW
12.7.3 Products/Services Offered
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategies
12.8 MERCK KGGA
12.8.1 COMPANY OVERVIEW
12.8.2 Financial Overview
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 CORNING INCORPORATED
12.9.1 COMPANY OVERVIEW
12.9.2 Financial Overview
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 CN BIO INNOVATIONS LTD
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 DATA CITATIONS